Associated material
Tools
- Sign up for article alerts
- Download references
- Download XML
- Email to a friend
- Order reprints
- Post a comment
Citeulike
Connotea
Del.icio.us
Facebook
Mendeley
Twitter
Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases
-
* Corresponding author: David G Nathan david_nathan@dfci.harvard.edu
Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
Genome Medicine 2009, 1:114 doi:10.1186/gm114
Published: 9 December 2009Abstract
The lysosomal storage diseases, such as Gaucher's disease, mucopolysaccharidosis I, II and IV, Fabry's disease, and Pompe's disease, are rare inherited disorders whose symptoms result from enzyme deficiency causing lysosomal accumulation. Until effective gene-replacement therapy is developed, expensive, and at best incomplete, enzyme-replacement therapy is the only hope for sufferers of rare lysosomal storage diseases. Preventive strategies involving carrier detection should be a priority toward the successful management of these conditions.